Investigational Drug Information for PLX3397
✉ Email this page to a colleague
What is the drug development status for PLX3397?
PLX3397 is an investigational drug.
There have been 24 clinical trials for PLX3397.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 20th 2020.
The most common disease conditions in clinical trials are Giant Cell Tumors, Giant Cell Tumor of Tendon Sheath, and Melanoma. The leading clinical trial sponsors are Plexxikon, Daiichi Sankyo, Inc., and Daiichi Sankyo Co., Ltd.
There are forty-four US patents protecting this investigational drug and five hundred and thirty-four international patents.
Summary for PLX3397
| US Patents | 44 |
| International Patents | 534 |
| US Patent Applications | 293 |
| WIPO Patent Applications | 292 |
| Japanese Patent Applications | 82 |
| Clinical Trial Progress | Phase 3 (2020-10-20) |
| Vendors | 58 |
Recent Clinical Trials for PLX3397
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan | Daiichi Sankyo Co., Ltd. | Phase 2 |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib | Daiichi Sankyo, Inc. | Phase 4 |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | Daiichi Sankyo Co., Ltd. | Phase 3 |
Clinical Trial Summary for PLX3397
Top disease conditions for PLX3397
Top clinical trial sponsors for PLX3397
US Patents for PLX3397
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PLX3397 | ⤷ Try a Trial | Synthesis of a compound that modulates kinases | Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP) | ⤷ Try a Trial |
| PLX3397 | ⤷ Try a Trial | Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Try a Trial |
| PLX3397 | ⤷ Try a Trial | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)m- ethyl)-2,2-difluoroacetamide | Celgene Corporation (Summit, NJ) | ⤷ Try a Trial |
| PLX3397 | ⤷ Try a Trial | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | AB SCIENCE (Paris, FR) | ⤷ Try a Trial |
| PLX3397 | ⤷ Try a Trial | Kinase modulation, and indications therefor | Plexxikon Inc. (Berkeley, CA) | ⤷ Try a Trial |
| PLX3397 | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PLX3397
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PLX3397 | Australia | AU2016258027 | 2035-05-06 | ⤷ Try a Trial |
| PLX3397 | Brazil | BR112017023490 | 2035-05-06 | ⤷ Try a Trial |
| PLX3397 | Brazil | BR112017023540 | 2035-05-06 | ⤷ Try a Trial |
| PLX3397 | Canada | CA2984899 | 2035-05-06 | ⤷ Try a Trial |
| PLX3397 | Canada | CA2984910 | 2035-05-06 | ⤷ Try a Trial |
| PLX3397 | China | CN107531706 | 2035-05-06 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
